Latest Updates
News
DECEMBER 2024
Congratulations to Our PMx expert, Catherine M Sherwin Ph.D. for her latest publication on "Optimal Dosing in Pediatrics"!
We are excited to share that our pharmacometrics expert, Catherine M. Sherwin, Ph.D., has recently published a study on The Journal of Pediatric Pharmacology and Therapeutics (JPPT) titled "Optimal Dosing Recommendations of Clonidine in Critically Ill Pediatric Patients Using Population Pharmacokinetics." Clonidine is widely used in the pediatric population f...
READ ARTICLE
SEPTEMBER 2024
A multi-scale semi-mechanistic CK/PD model for CAR T-cell therapy
Publication of new article co-authored by Differentia's CEO, Dr. Kas Subramanian PhD, showing detailed results for modeling of the CAR T cell response, a semi-mechanistic model to explore variability in response due to patient- and drug-specific properties: "A multi-scale semi-mechanistic CK/PD model for CAR T-cell therapy" Link: Frontiers | A...
READ ARTICLE
OCTOBER 2024
Our Pharmacometrics and Clinical Pharmacology expert, Catherine M. Sherwin, Ph.D., has been recognized as an AAPS Fellow
Exciting news! Our Pharmacometrics & Clinical pharmacology expert, Catherine M Sherwin Ph.D., was recognized by the American Association of Pharmaceutical Scientists (AAPS) for her considerable contribution to the field of Pharmacometrics and inducted as an AAPS Fellow at the #PharmaSci360 in Salt Lake City. Dr. Sherwin is Differentia's...
READ ARTICLEAUGUST 2024
Groundbreaking Platform first applied to rare autoimmune disorder, IgG4-RD to uncover new treatment targets
Differentia Biotech, a leader in model-informed drug development, is proud to announce the launch of its innovative autoimmune disease platform. This platform integrates Artificial Intelligence and Machine Learning (AI/ML) with Quantitative Systems Pharmacology (QSP) extracting disease understanding by combining insights from patient-specifi...
READ ARTICLE
AUGUST 2024
Highlights from Dr. Kalyanasundaram Subramanian's Presentation at T20 Bio Tonacea Conference 2024
The T20 Bio Tonacea Conference 2024 witnessed a landmark presentation by Dr. Kalyanasundaram Subramanian, CEO of Differentia and a Fellow of the Indian National Academy of Engineering. His keynote, titled “Applications of Quantitative Systems Pharmacology (QSP) in ADC New Drug Development,” provided a comprehensive overview...
READ ARTICLE